Silence Therapeutics said this week that it has identified the maximum tolerated dose for its siRNA-based cancer treatment Atu027 and that the drug has proven safe and well-tolerated in a nearly complete phase I trial.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.
The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.
The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.
Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."